Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C.
Barbara Burtness
Consultant or Advisory Role - Bristol-Myers Squibb
Ju-Whei Lee
No relevant relationships to disclose
Donghua Yang
No relevant relationships to disclose
Fang Zhu
No relevant relationships to disclose
Joaquin J. Garcia
No relevant relationships to disclose
Arlene A. Forastiere
No relevant relationships to disclose
Christine H. Chung
Consultant or Advisory Role - Bristol-Myers Squibb